SunOpta (NASDAQ:STKL), a leading pioneer in sustainable, plant-based food and beverage supply chain solutions, announced today that its shareholders have overwhelmingly approved the company’s acquisition by an affiliate of Refresco Holding.
Merck (NYSE:MRK), operating as MSD outside the U.S. and Canada, announced today that the European Commission (EC) has granted marketing authorization for ENFLONSIA™ (clesrovimab).
APi Group (NYSE:APG) today announced a major step in its international growth strategy, entering into a definitive agreement to acquire Wtech Fire Group.
Ally Financial (NYSE:ALLY) delivered a powerful performance for the first quarter of 2026, headlined by an adjusted earnings per share of $1.11—an approximate 90% surge compared to the same period last year.
Kustom Entertainment (NASDAQ:KUST) and Cycurion (NASDAQ:CYCU) have announced a definitive move to restructure the terms of their previously proposed transaction regarding Kustom’s legacy video solutions segment.
Canadian Solar (NASDAQ:CSIQ) announced a milestone victory in its ongoing intellectual property battle with Trina Solar.
Polestar (NASDAQ:PSNY) delivered a year of aggressive top-line expansion in 2025, according to its full-year financial results released today.
Truist Financial (NYSE:TFC) reported first-quarter 2026 net income available to common shareholders of $1.4 billion, or $1.09 per diluted share.
Fifth Third Bancorp (NASDAQ:FITB) reported first-quarter 2026 results that reflect both the massive scale and the immediate financial hurdles of its recent $12.7 billion acquisition of Comerica.
Autoliv (NYSE:ALV), the global leader in automotive safety systems, reported first-quarter 2026 financial results that surpassed analyst consensus, driven by robust market share gains in Asia.
Kandal M Venture (NASDAQ:FMFC), a specialist contract manufacturer of affordable luxury leather goods, today issued optimistic guidance for the full fiscal year ended March 31, 2026.
Kura Oncology (NASDAQ:KURA) today presented encouraging preliminary data from a subset analysis of its ongoing FIT-001 clinical trial at the 2026 International Kidney Cancer Symposium.
